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Abstract: 
Background:  The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first 
described in 2012 and attracted a great international attention due to multiple healthcare 
associated outbreaks.  The disease carries a high case fatality rate of 34.5%, and there is no 
internationally or nationally recommended therapy. 
Method:  We searched MEDLINE, Science direct, Embase and Scopus databases for relevant 
papers published till March 2019 describing in vitro, in vivo or human therapy of MERS. 
Results:  Initial search identified 62 articles: 52 articles were from Medline, 6 from Embase, and 
4 from science direct. Based on the inclusions and exclusions criteria, 30 articles were included 
in the final review and comprised:  22 in vitro studies, 8 studies utilizing animal models, 13 
studies in humans, and one study included both in vitro and animal model.  There are few 
promising therapeutic agents in the horizon.  The combination of lopinavir/ritonavir and 
interferon- beta- 1b showed excellent results in common marmosets and currently is in a 
randomized control trial.  Ribavirin and interferon were the most widely used combination and 
experience comes from a number of observational studies. Although, the data are heterogenous, 
this combination might be of potential benefit and deserve further investigation. There were no 
randomized clinical trials to recommend specific therapy for the treatment of MERS-CoV 
infection.  Only one such study is planned for randomization and is pending completion.  The 
study is based on a combination of lopinavir/ritonavir and interferon- beta- 1b.  A fully human 
polyclonal IgG antibody (SAB-301) was safe and well tolerated in healthy individuals and this 
agent may deserve further testing for efficacy. 
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Conclusion: Despite multiple studies in humans there is no consensus on the optimal therapy for 
MERS-CoV.  Randomized clinical trials are needed and potential therapies should be evaluated 
only in such clinical trials.  In order to further enhance the therapeutic aroma for MERS-CoV 
infection, repurposing old drugs against MERS-CoV is an interesting strategy and deserves 
further consideration and use in clinical settings. 
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Introduction: 
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first identified in 2012 and 
since then the disease attracted an increased international interest to resolve issues related to the 
epidemiology, clinical features, and therapy.  This interest is further enhanced by the fact that 
MERS-CoV infection resulted in 2428 cases in 27 countries around the world as of June 23, 
2019 [1] and most of the cases are linked to the Middle East [2].  So far there had been three 
patterns of the transmission of MERS-CoV virus mainly: sporadic cases [3], intra-familial 
transmissions [4–6] and healthcare-associated transmission [3,7–26].  The disease carries a high 
case fatality rate of 34.5% [1] and so far there had been no proven effective therapy and no 
approved therapies for MERS-CoV infection by international or national societies.  Few 
therapeutic agents were reported in the literature but all were based on retrospective analysis.  In 
this study, we review available literature on the current therapeutic options for the disease 
including in vitro, animal studies, and studies in human. 
Search strategy 
We searched four electronic databases: MEDLINE, Science direct, Embase and Scopus for 
articles in accordance with the referred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [27].  We used the following terms: 
#1: “Middle East Respiratory Syndrome Coronavirus” OR “MERS virus” OR “MERS Viruses” 
OR “MERS-CoV” OR “Novel Coronavirus” AND 
#2: “Drug effect” OR “Drug Therapy” OR “Combination drug therapy” OR “Drug Ther*” OR 
“Combination drug ther*” 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
5 
 
In addition, we reviewed the references of retrieved articles in order to identify additional studies 
or reports not retrieved by the initial search.  The included studies were arranged as: in vitro 
studies, animal studies and human studies.  We included studies conducted in the vitro, animal, 
or humans that measured the impact of drug therapy against MERS-CoV.  We excluded studies 
that examined the impact of drug therapy against Coronaviruses other than MERS-CoV, any 
study that focused on drug synthesis and extractions, review articles, studies of supplemental 
therapy, and articles focused on the mechanism of action of medications. 
Results: 
Initial search identified 62 articles: 52 articles were from Medline, 6 articles from Embase, and 4 
articles from science direct. Of those, 32 studies were excluded: review studies (n=16), drug 
synthesis and extraction (n=3), supplemental therapy (n=1), drug therapy in Coronavirus in 
general (n=4), and site of action of different drugs modalities (n=8).  Based on the inclusions and 
exclusions criteria, only 30 articles were included in the final review:  13 studies were conducted 
in vitro, 8 studies were done in animal models, 8 studies were done in humans, and one study 
included both in vitro and animal model (Figure 1). 
In Vitro Studies: 
There were many in vitro studies evaluating various agents against MERS-CoV such as: 
interferon (INF), ribavirin, and HIV protease inhibitors (nelfinavir, ritonavir and lopinavir) as 
summarized in table 1.  In vitro studies showed that IFN- β has a lower 50% inhibitory 
concentration (IC50) for MERS-CoV compared with IFN-a2b [28]..  In addition,  IFN-β  has a 
superior anti-MERS-CoV activity in the magnitude of 16-, 41-, 83- and 117-fold higher 
compared to IFN-α2b, IFN-γ, IFN-universal type 1 and IFN-α2a, respectively [28].  Pegylated 
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Interferon-α (PEG-IFN-α) inhibited the effect of MERS-CoV at a dose of 1 ng/ml with complete 
inhibition of cytopathic effect (CPE) at doses of 3-1000 ng/ml in MERS-CoV infected Vero cells 
[29].  
Ribavirin, a nucleoside analog requiring activation by host kinases to a nucleotide, required high 
in vitro doses to inhibit MERS-CoV replications and these doses are  too high to be achieved in 
vivo [30,31].  The combination of interferon- alfa 2b (INF-α2b) and ribavirin in Vero cells 
resulted in a an 8-fold reduction of the IFN-α2b dose and a 16-fold reduction in ribavirin dose  
[30].  
The HIV protease inhibitors, Nelfinavir and lopinavir, were thoughts to inhibit MERS-CoV 
based on results from SARS [32].  Nelfinavir mesylate hydrate and lopinavir showed suboptimal 
50% effective concentration (EC50) in the initial CPE inhibition assay and were not evaluated 
further [31].  In another study, the mean EC50 of lopinavir  using Vero E6 and Huh7 cells was 8.0 
µM [33].   
MERS-CoV requires fusion to the host cells to replicate, thus MERS-CoV fusion inhibitors such 
as camostat and the Heptad Repeat 2 Peptide (HR2P) were evaluated in vitro [34,35].  Camostat 
inhibited viral entry into human bronchial submucosal gland-derived Calu-3 cells but not 
immature lung tissue [34].  HR2P was shown to inhibit MERS-CoV replication and the spike 
protein-mediated cell-cell fusion [35].  Camostat was effective in reducing viral entry by 15-
folds in the Vero-TMPRSS2 cells infected with MERS-CoV [36].  
Nitazoxanide, a broad-spectrum antiviral agent, and teicoplanin, an inhibitor of Cathepsin L in 
the Late Endosome/Lysosome cycle and a blocker of the entry of MERS-CoV, showed inhibitory 
effects of MERS-CoV in vitro [37,38].   
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The ability of recombinant receptor-binding domain (RBD-Fd) to inhibit MERS-CoV has been 
studied in DPP-4 expressing Huh-7 infected cells. The 50% inhibition dose (ID50) for RBD-Fd 
was 1.5 µg/ml compared with no inhibitory activity in untreated cells even at highest dose [39].  
Cyclosporin affects the function of many cyclophilins that act as chaperones and facilitate 
protein folding [29,40].  In vitro, cyclosporine inhibited MERS-CoV replication [29,40].  Three 
days post infection, cytopathic effects (CPE) of MERS-CoV was inhibited by Cyclosporine Vero 
cells and mock-infected Huh7 cells [29].   
Toremifene, Chlorpromazine, and Chloroquine were evaluated using Vero cells, human 
monocyte-derived macrophages (MDMs) and immature dendritic cells (MDDCs) [41]. These 
drugs were transferred to cells one hour prior to infection with MERS-CoV. After 48 hours, viral 
replication was inhibited by Toremifene with 50% effective concentration (EC50) of 12.9 µM) 
but the MDMs dose was too low to have a calculated EC50. Chlorpromazine inhibited MERS-
CoV in Vero cells with an EC50 of 9.5 µM and no cytotoxicity.  In MDMs cells, the EC50 was 
13.58 µM with high 50% cytotoxicity concentration (CC50) of 25.64 µM.  Chloroquine showed 
no antiviral activity in the MDMs. Toremifene reduced virus by 1–1.5 log10 at a dose more than 
20 µM. Chlorpromazine reduced MERS-CoV by 2 log10 and had a narrow therapeutic window 
and a high toxicity [41].  
Chloroquine, Chloropromazine, and loperamide were tested on Huh7 cells [43]. The cells were 
treated 1-hour prior to infection. Antiviral activity of chloroquine was dose-dependent.  
Chlorpomazine showed activity against MERS-CoV with EC50 of 4.9 ± 1.2 µM and CC50 of 
21.3 ± 1.0 µM.    Loperamide, an antidiarrheal drug, inhibited MERS-CoV and induced CPE.  
Two kinase signaling (ABL1) pathway inhibitors (Imatinib mesylate and Dasatinib) were active 
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against MERS-CoV in vitro [42].  In Vero E6 and MRC5 cells  imatinib had a dose dependent 
killing [43].   
Saracatinib has a broad-spectrum antiviral activity against different strain of MERS-CoV. After 
72 hours of infection of Huh-7 cells, Saracatinib exhibited an EC50 of 2.9 µM and CC50 of more 
than 50 µM [44].  Whereas, gemcitabine was shown to be effective against MERS-CoV infected 
Huh-7 cells with an EC50 of 1.2 µM and a complete viral depletion at a dose of ≥ 1 µM [44].  
Inhibitory effect of resveratrol against MERS-CoV was tested using infected Vero E6 cells.  
After 48 hours, cell death was significantly reduced in the treatment group with resveratrol. The 
study showed that resveratrol inhibited MERS-CoV after entry in the cells and when resveratrol 
was added at same time of MERS-CoV, there was no difference in cell proliferations and viral 
titers compared with cells treated after infections  [45]. 
The antiviral activity of GS-441524 and its pro-drug GS-5734 (Remdesivir) were tested on 
MERS-CoV infected human airway epithelial cell (HAE) [46]. GS-441524 has a mean EC50 of 
0.86 µM and GS-5734 has a mean EC50 of 0.074 µM with more reduction in viral titer if the 
drug was added 24-72 hours post infection [46]. 
 Utilizing HAE cells infected with MERS-CoV, there was a significant reduction in viral 
replication and dsRNA level when cells were treated with K22 compound [47].  A novel peptide 
(P9) showed an in vitro activity against MERS-CoV at an IC50 of 5 µg/ml and  more than 95% 
infection reduction at concentration higher than 25 µg/ml [48].  The two neurotransmitter 
antagonists (Chlorpromazine hydrochloride and triflupromazine hydrochloride) inhibit MERS-
CoV infected Vero E6 cells [42]. The DNA synthesis and repair inhibitor, Gemcitabine 
Hydrochloride, and an Estrogen receptor I antagonist, Toremifene citrate, had antiviral activity 
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against MERS-CoV [42].  An Estrogen receptor I antagonist, Toremifene citrate, had activity 
against MERS-CoV [42].  In addition, MERS-CoV is inactivated by amotosalen and ultraviolet 
light in fresh frozen plasma [49]. 
Animal Studies: 
Monoclonal antibodies against MERS-CoV had been tested in animal models of MERS-CoV 
infection. The monoclonal antibodies, 3B11-N and 4E10-N,  were compared with no treatment in 
Rhesus Monkey model [50]. Antibodies, 3B11-N, were administered as a prophylaxis one-day 
prior to animal inoculation and showed significant reduction in lung disease radiographically.   
However, there was no significant diffrence when 3B11-N and 4E10-N were compared in term 
of lung pathology (P=0.1122) [50] .  
Interferon alfa-2a in conjunction with ribavirin were tested in rhesus macaques model of MERS-
CoV infection. The animals were randomly assigned to either treatment or control groups and 
therapy was started eight hours post-infection. Necropsy showed a normal appearance of the lung 
in the treatment group compared with the control group. Virus replication was significantly 
reduced in the lung of treated animal. Serum interferon alfa was 37 times the level in untreated 
group by day 2.  In addition, the treated group showed reduced systemic and local levels of pro-
inflammatory markers such as interleukin-2, monocyte chemotactic protein-1, interleukin-2 
receptor antagonist, interleukin-6, interleukin-15, and interferon-gamma [51].  
Another study was conducted utilizing 12 healthy common marmosets inoculated with MERS-
Cov and then assigned to four groups (control group; Mycophenolate mofetil intraperitoneally 8 
hours after inoculation; Lopinavir with Ritonavir at 6, 30, and 54 hours after inoculation; or 
Interferon- Beta-1b subcutaneous at 8- and 56-hours post inoculation) [52]. Lopinavir/Ritonavir 
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and Interferon- beta- 1b treated groups had better clinical scores, less weight reduction, less 
pulmonary infiltrate, and lower viral load than the untreated group. The Mycophenolate group 
had a higher viral load with severe disease compared with the control group. The fatality rate 
was higher in untreated, and Mycophenolate treated groups (67%) than Lopinavir/Ritonavir 
treated and Interferon-Beta-1 b treated groups (0-33%) after 36 hours of inoculation [52].  
The human dipeptyl peptidase-4 (hDPP4) is a receptor for cell binding and entry of MERS-CoV.  
A transgenic mouse model with hDPP4 was utilized to test the effects of humanized mAb (hMS-
1).  In the model, a single dose of hMS-1 protected the transgenic mouse from MERS-CoV 
infection and all control mice died ten days post-infection [53].  
The Humanized antibodies mAb 4C2h are mouse-derived neutralizing spike receptor-binding 
domain of MERS-CoV (MERS-RBD) that were further humanized [54].  A single intravenous 
dose was injected one day pre and post MERS-CoV inoculation and showed that h-mAb-4C2h 
significantly decreased viral titer in the lungs in the mouse model (p <0.05) [54]. 
Another study was done on adenoviruses expressing hDPP4 in mouse lungs (Ad5-hDPP4- 
Transduced mice) utilizing intranasal peptide derived from the heptad repeat (HR) 2 domain in 
S2 subunit known as HR2P analogue (HR2P-M2) [55]. The animals were either given intranasal 
HR2P-M2 six hours before infections or a control group with no treatment. The treated group 
showed decreased in the viral titer compared with the control group. The combination of HR2P-
M2 with interferon β showed further reduction of infection [55].  
The human-Fc-fused version of neutralizing nanobody (NbMS10-Fc) was tested using hDPP-4 
transgenic mice model of MERS-CoV infection. The mice were injected with a single dose 
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NbMS10-FC or Trastuzumab (control group) before a lethal dose of MESR-CoV. The treatment 
group had a 100% survival rate compared with 0% survival rate in the control group [56].  
The impact of a trans-chromosomic (Tc) bovine, fully human polyclonal immunoglobulin G 
(IgG) antibodies were tested on Ad5-hDPP4-transduced mice five days after transduction and 12 
hours before inoculated MERS-CoV.  Animals received either intraperitoneal SAB-301 or 
control or Tc hIgG group. Viral load was lower in  mice treated with SAB-301 at day 1 and 2 
post-infection [57].   
A recombinant trimeric receptor-binding protein (RBD-Fd) was tested on hDPP4 transgenic 
mice infected with MERS-CoV. The animals received RBD-Fd subcutaneously and were 
boosted at 3 weeks, 6 weeks, and 6 months. RBD-Fd induced S1-specific IgG antibodies against 
MERS-CoV and was maintained for at least 6 months.   The survival rate in RBD-Fd immunized 
mice was 83% [39]. 
Human Studies: 
The first use of antiviral agents to treat MERS-CoV infection was observed in 5 patients in 2013 
in Saudi Arabia [58].  All patients received ribavirin orally and subcutaneous interferon alfa-2b. 
Unfortunately, all patients died at 1-2 months due to respiratory and multi-organ failure and four 
patients experienced adverse drug reaction such as thrombocytopenia, anemia and pancreatitis 
[58]. 
In 2015, two patients with MERS-Cov infection in Kuwait were treated with pegylated interferon 
alfa-2b subcutaneously and oral ribavirin [59].  One patient was discharged home after 42 days 
of starting antiviral therapy and ribavirin was stopped after one week of therapy due to anemia. 
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The second patient recovered from MERS-CoV and he subsequently died two months later  with 
multidrug-resistant organism [59].   
A large retrospective cohort study included 44 adult patients. Of those patients, 24 patients 
(control group) did not receive antiviral treatment, and 20 patients received subcutaneous 
pegylated interferon alfa-2a and oral ribavirin [60] per previously developed protocol [61]. The 
survival rate after 14 days from the date of diagnosis was statistically higher in the treatment 
group compared with the control group (70% versus 29%; P= 0.004).  However, the survival rate 
did not differ in the two groups at 28 days (30% versus 17%; P= 0.054) [60]. 
In 2014, a retrospective cohort study was conducted on 24 confirmed MERS cases in Jeddah, 
Saudi Arabia and were started on day one of MERS-CoV confirmation [62]. Of those patients, 
13 received interferon α-2a subcutaneous per week and 11 patients received interferon β-1a 
subcutaneous three times weekly. Both groups also received ribavirin orally.  The case fatality 
rate was 85% in INF-α-2a versus 64% in INF-β-1a (p= 0.24). The fatality rate in patients using 
INF with positive MERS-CoV RT-PCR was 90% versus 44% in those with negative MERS-
CoV RT-PCR test [62].  
  In 2015, pegylated interferon-α-2b and ribavirin was given to two confirmed cases in Riyadh. 
One patient was treated PEG-INF- α-2b and ribavirin and start to improve day 6 and had 
complete recovery at day 18. The second case was not a confirmed case and was started on these 
medication as a prophylaxis. On the fourth day, the patient started to improve and was 
discharged home after two weeks [63]. The combination therapy was also used in other case 
reports, (table 3) [64,65].   
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In a large cohort study of 51 patients, various combinations of interferon and ribavirin were used 
with different outcomes (table 3) [66].  Another small study  utilized ribavirin and interferon-alfa 
2b in three patients who received therapy within 1-2 days of admission and were compared to 
three other patients who received therapy 12-19 days after admission [67].  The first group 
survived and the latter group died [67].  The use of interferon beta, interferon alpha, and ribavirin 
was associated with  survival rates of 78.3%, 75%, and 68.4%, respectively [66].   
Oral lopinavir and ritonavir were used for the treatment of a 64 years old Korean male with 
confirmed MERS-CoV infection. These medications were started on the fourth day of admission 
and the patient achieved full recovery after nine days of treatment [63].  One patient was treated 
with pegylated interferon, ribavirin and lopinavir/ritonavir and viremia was detected for two days 
following therapy with triple therapy [64].   In a case series, eight patients received 
mycophenolate mofetil and all survived [66]. 
A phase 1 randomized placebo-controlled study utilized a fully human polyclonal IgG antibody 
(SAB-301) and evaluated the safety and tolerability of this agent in 28 adults compared with 10 
adults who received placebo [68].  The trial was registered with ClinicalTrials.gov, number 
NCT02788188.   SAB-301 was well tolerated and the most reported adverse events were 
headache, elevated creatinine kinase, and albuminuria [68]. 
Discussion: 
Since the emergence of MERS-CoV infection there was a large interest in the development of an 
effective therapy for this disease.  In this review, we summarized the available literature on 
possible therapeutic options including in vitro, animal and human studies.   In vitro studies 
showed superiority of IFN-β  compared to IFN-α2b, IFN-γ, IFN-universal type 1 and IFN-α2a 
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[28] and PEG-IFN-α had excellent CPE inhibition [29].  Moreover, the combination of INF-α2b 
and ribavirin in Vero cells showed augmentation of action and facilitates the reduction of the 
doses of IFN-α2b and ribavirin to lower concentrations suggesting possible utility in clinical use  
[30].  Saracatinib with Gemcitabine had no difference in cytotoxicity compared with Saracatinib 
alone but was less cytotoxic compared with gemcitabine alone [44].  There were many drugs that 
were used in vitro and showed effectiveness, however, translating the findings from these studies 
into clinical trial remains of particular importance especially taking into consideration 
availability, pharmacokinetic properties, pharmacodynamic characteristics and possible side 
effects [69]. 
Avaialble clincial experience regarding the therapy for MERS-CoV relies on limited case reports 
and observational case-series.   The most widely used combination is ribavirin and IFN and 
experience comes from limited case reports and a number of observational studies.  These 
studies are non-homogeneous in nature and thus a common conclusion could not be obtained to 
make firm recommendations for the use of this combination in routine clinical practice outside of 
prospective clinical studies [69].    
The combination of lopinavir/ritonavir and interferon- beta- 1b was used in common marmosets 
[52] and was used in two patients with good outcome [63–65].  This combination is being 
considered in a randomized control trial in Saudi Arabia. The enrollment for the study began in 
November 2016 and the results are not available yet [70]. The study was registered on 27 July 
2016 at ClinicalTrials.gov, with an ID: NCT02845843. And this is the only currently ongoing 
clinical therapeutic trial for MERS-CoV therapy. 
In conclusion, despite multiple studies in humans there is no consensus on the optimal therapy 
for MERS-CoV.  Randomized clinical trials are needed and potential therapies should be 
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evaluated only in such clinical trials.  Thus, any such therapy should be used in conjunction with 
clinical trials.  An interesting strategy is repurposing old drugs against MERS-CoV and this 
deserves further consideration and use in clinical setting 
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Figure 1: A flow diagram of the search strategy according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA)  guidelines [27] 
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Table 1: A summary of in Vitro Studies evaluating medications against MERS-CoV 
 Study type Cell Type Treatment  Outcome 
[29] In vitro 
Comparator 
study 
MERS-CoV infected 
Vero cells and mock-
infected Huh7 cells. 
Cyclosporin 3 µg 
DMSO (a solvent 
control Control) 
No change in CPE 
Cyclosporin 9 µg 
DMSO (a solvent 
control Control) 
CPE inhibited and no change on the cell viability on the infected 
Vero cells compared with mock-infected cells 
MERS-CoV infected 
Huh7 cells and mock-
infected Huh7 cells. 
Cyclosporin 3.75 µg, 
7.5 µg, and 15 µg 
 
CPE reduced or inhibited by 7.5 µg and 15 µg Cyclosporine.  
 
MERS-CoV infected 
Vero cells 
PEG-INF-α2b at t= -
4h, t= 0h, or t= 4h of 
CPE reduced at 1 ng/ml and complete inhibition at doses 3, 10, 30, 
100, 300, or 1000 ng/ml. 
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infection at doses 
range from 0 ng/ml to 
1000 ng/ml 
[30] In vitro 
Comparator 
study 
hCoV-EMC infected 
Vero cells 
INF-α2b IC50 = 58.08 U/ml, IC90 =320.11 U/ml, and IC99= 2061.89 U/ml 
CPE reduced at 250 U/ml and complete inhibition at ≥ 1000 U/ml 
Genome copies reduced by 0.53-log at 500 U/ml and highest 
reduction by 1.84-log at 5000 U/ml.  
Viral titer reduced by 0.57-log at 500 U/ml and highest reduction 
by 1.31-log at 5000 U/ml. 
Ribavirin IC50 = 41.45 µg/ml, IC90 = 92.15 µg/ml, and IC99 =220.40 µg/ml 
CPE reduced at 100 µg/ml and complete inhibition at ≥ 200 µg/ml. 
Genome copies reduced by 0.82-log at 500 µg/ml and highest 
reduction by 2.04-log at 2000 µg/ml. 
Viral titer reduced by 1.24-log at 100 µg/ml and highest reduction 
by 4.05-log at 2000 µg/ml. 
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INF-α2b + Ribavirin CPE reduced at 12 µg/ml Ribavirin and 62 U/ml INF-α2b and 
complete inhibition at 25 µg/ml Ribavirin and 125 U/ml INF-α2b 
Ribavirin + INF-α2b at 1:5, Viral titer reduced by 0.4 to 2.16-log 
compared with INF-α2b alone. 
LLC-MK 2 infected 
cells 
INF-α2b  IC50 = 13.26 U/ml, IC90 = 44.24 U/ml, and IC99 =164.73 U/ml.  
Reduced viral protein level with increased dose starting at 250 
U/ml. 
Viral titer reduced by 3.97-log at 2000 U/ml  
Ribavirin IC50 = 16.33 µ/ml, IC90 = 21.15 µg/ml, and IC99 = 28.02 µg/ml. 
Reduced viral protein level with dose 50  µg/ml (Not dose 
dependent) 
Viral titer reduced below the detection threshold of 13.7 
TICD50/ml at 200 µg/ml 
INF-α2b + Ribavirin Reduced viral protein level with dose INF-α2b 250U/ml and 
Ribavirin at 50 µg/ml. 
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[41] In vitro 
Comparator 
study 
Vero cells Toremifene EC50 = 12.9 µM with no virus reduction 
Chlorpromazine EC50 = 9.5 µM with no cytotoxicity 
Virus reduction by 3.1 log10 if dose >15µM  
Chloroquine No virus reduction 
MDMs Toremifene Dose treated too low to determine EC50 with high cytotoxicity. 
Virus reduction by 1-1.5 log10 if dose >20µM with increased in the 
toxicity. 
Chlorpromazine EC50 = 13.58 µM with high cytotoxicity CC50 = 25.64 µM, SI was 
1.9 
Virus reduction by 2 log10 with narrow therapeutic window and 
high toxicity 
Chloroquine No antiviral activity and no cytotoxicity. 
MDDCs Toremifene Virus reduction by 1-1.5 log10 if dose >20µM with increased in the 
toxicity. 
Chlorpromazine Virus reduction by 2 log10 with narrow therapeutic window and 
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high toxicity 
Chloroquine No antiviral activity and no cytotoxicity 
[33] In vitro 
Comparator 
study 
Huh7 cells Chloroquine 
Chlorpromazine 
Loperamide 
Lopinavir 
Pre-infection 
Chloroquine: dose-dependent, EC50 = 3.0 ±1.1 µM and CC50 = 
58.1 ±1.1 µM, SI was 19.4 
Chlorpromazine: Complete inhibition at 12 µM, EC50 = 4.9 ±1.2 
µM and CC50 = 21.3 ±1.0 µM, SI was 4.3 
Loperamide: Complete inhibition at 8 µM, EC50 = 4.8 ±1.5 µM 
and CC50 = 15.5 ±1.0 µM, SI was 3.2 
Lopinavir: Complete inhibition at 12 µM, EC50 = 8 ±1.5 µM and 
CC50 = 24.4 ±1.0 µM, SI was 3.1 
[43] In vitro 
Comparator 
study 
Vero E6 
MRC5 
Imatinib in the first 
4hrs of infection 
versus 5 hrs post 
infection 
Iamtinib at time of infection is dose dependent. 
Viral level higher at post-infection compared to before infection 
(P< 0.05) 
Genomic RNA inhibited if drug added before infection (P< 0.05) 
but no effect if added post-infection 
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CCF2 cleavage reduced by 80% (P< 0.001)  
[49] In vitro 
Comparator 
study 
Pooled Plasma 
inoculated with 
MERS-CoV 
Amotosalen and 
Ultraviolet A light 
Viral titer reduced by 4.67 ± 0.25 log pfu/ml with no detection of 
the viable viruses. 
Viral genomic titer by RT-qPCR: no viral RNA had been detected 
on the treated cells 
[44] In vitro 
Comparator 
study 
Huh-7 cells infected 
with MERS-CoV 
Saracatinib MERS-CoV infected cells: EC50 = 2.9 µM and CC50 > 50 µM, SI 
>17,  
Dose 1 µM: viral titer reduced by > 50% (P<0.05) with no effect 
on viral N protein after 24 hrs 
Dose 10 µM: reduced by 90% (P<0.05) with complete depletion 
on the viral N protein after 24 hrs.   
Complete inhibition of viral genomic RNA and mRNA synthesis 
(P<0.0001) 
Viral titer: 
Pretreatment: no difference  
At time of infection: marked reduction with significant a decrease 
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of viral genomic RNA and mRNA synthesis. 
Post treatment (within 2 hrs.): complete inhibition (P< 0.0001) 
Post treatment (after 4hrs): less effect (P<0.05) 
Huh-7 cells infected 
with rMERS-Cov. 
Saracatinib rMERS-CoV infected cells: EC50 = 9.3 µM 
Huh-7 cells infected 
with rMERS-Cov-S2. 
Saracatinib rMERS-CoV-S2 infected cells: EC50 = 9.0 µM 
Huh-7 cells infected 
with MERS-CoV 
Gemcitabine EC50 = 1.2 µM with complete viral depletion at dose ≥ 1 µM 
Saracatinib + 
Gemcitabine  
Synergistic effect at combination index of 0.529 
Cytotoxicity: no difference compared with Saracatinib and less 
compared with Gemcitabine  
[45] In vitro 
Comparator 
study 
Vero E6 Resveratrol Reduced cell death at 125-250 µM (MTS assay P<0.05, neutral red 
uptake assay P< 0.005) 
Less cytotoxicity even at higher concentration. 
Viral RNA level: 
At concentration 31.25-250 µM: after 48hr lower than after 24 hrs 
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After 48 hr at concentration 150µM: lower (P<0.05), at 
concentration 200µM (P<0.01), at concentration 250µM 
(P<0.001). 
If the drug added at time of infection: no difference in the cell 
proliferations and viral titers. 
After 24hr, the inhibition of N protein is dose dependent manner. 
At concentration 150µM: limited decrease in the N protein 
At concentration 250µM: elimination of N protein. 
Inhibited Caspase 3 cleavage: dose dependent manner. 
If drug administered consecutively at lower dose:  
Ever 24 hrs, dose ≤ 62.5 µM: the cell proliferation and cells 
viability were higher compared with untreated group (P < 0.001). 
The cytotoxicity and viral titer were lower (P < 0.001) 
[46] In vitro 
Comparator 
study 
HAE infected with 
MERS-CoV 
GS-441524 or 
Remdesivir (GS-5734) 
GS-44152: EC50 = 0.86 µM  
Remdesivir: EC50 = 0.074 µM 
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More reduction in viral titer if the drug were added 24-72 hrs. post 
infection. 
[47] In vitro 
Comparator 
study 
HAE infected with 
MERS-CoV 
K22 Significant reduction in the viral replication and dsRNA level. 
[48] In vitro 
Comparator 
study 
MERS-CoV infected 
cells 
Novel peptide (P9)  IC50 = 5 µg/ml 
>95% reduction at concentration > 25 µg/ml 
[36] In vitro 
Comparator 
study 
Vero-TMPRSS2 
infected cells 
Camostat At dose 10 µM, decreased viral entry by 15-fold 
 
Vero-TMPRSS2- 
negative infected cells 
Camostat At dose 10 µM, no effect on the viral entry  
Calu-3 cells Camostat At dose 10 µM, decreased viral entry by 10-fold 
Viral RNA suppressed by 90-fold 
Cell death delayed by 2 days post infection 
At dose 100 µM, Viral RNA suppressed by 270 folds 3 days post 
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infection 
Cell death delayed by 5 days post infection 
MRC-5 cells or WI-38 
cells 
Camostat No effect on the viral RNA at 3 days post infection. 
At dose 10 µM, there was no effect on the cell death 
At dose 100 µM, the cell death partially suppressed.  
Vero-TMPRSS2 
infected cells 
EST (an inhibitor of 
endosomal cathepsins) 
At dose 10 µM, slight inhibition of viral entry  
Vero-TMPRSS2- 
negative infected cells 
EST (an inhibitor of 
endosomal cathepsins) 
At dose 10 µM, inhibit viral entry 
Calu-3 cells EST (an inhibitor of 
endosomal cathepsins) 
At dose 10 µM, slight inhibition of viral entry 
Vero-TMPRSS2 
infected cells 
Camostat + EST (an 
inhibitor of endosomal 
cathepsins) 
Decreased viral entry by 180-fold 
Calu-3 cells 
MRC-5 cells 
Camostat + EST+ 
Leupeptin 
No significant difference in the viral entry 
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WI-38 cells Single treatment + 
Leupeptin 
Vero-TMPRSS2- 
negative infected cells 
Cathepsin L inhibitor 
Cathepsin K inhibitor 
 
Inhibit the viral entry by 40-fold 
Vero-TMPRSS2- 
negative infected cells 
Cathepsin B inhibitor 
Cathepsin S inhibitor 
 
No effect on the viral entry 
Calu-3 cells Leupeptin Dose dependent effect 
Blocked viral entry at 10-100 µM 
MRC-5 cells Leupeptin No effect on the viral entry 
WI-38 cells Leupeptin No effect on the viral entry 
[42] In vitro 
Comparator 
study 
Vero E6 cells infected 
with MERS-CoV 
Chlorpromazine EC50 = 9.51 µM with low toxicity 
Triflupromazine EC50 = 5.76 µM with low toxicity 
Imatinib EC50 = 14.69 µM with low toxicity 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
39 
 
 
 
 
 
* CPE: cytopathic effect; PEG-INF: pegylated interferon; INF: interferon; IC50: inhibitory concentration of 50% of cells, IC90: inhibitory concentration of 
90% of cells; IC99: inhibitory concentration of 99% of cells; EC50 and EC90: 50% and 90% maximal effective concentration; CC50: cytotoxicity concentration 
that kills 50% of cells; RT-qPCR: Real time Quantitative polymerase chain reaction;  
 
 
 
 
 
Dasatinib EC50 = 5.47 µM with low toxicity 
Nilotinib No significant inhibition of MERS-CoV 
Gemciatbine EC50 = 1.22 µM with low toxicity 
Toremifene EC50 = 12.92 µM with low toxicity 
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Table 2:  A summary of the use of anti-viral agents for the treatment of MERS-CoV infection in animal model 
 Study type Total # Supportive 
therapy 
Treatment plan Outcome 
 
[50] Comparator 
trial 
Rhesus 
monkey 
No  3B11-N antibody, 4E10-N antibody, 
or no treatment 1 day before 
inoculation (prophylaxis) 
Less abnormal lung volume and less 
Lung pathology 
[53] Comparator 
trial 
hDPP4-Tg 
mice 
No After 1 day of inoculation 
IV hMS-1 2mg/kg versus 
Trastuzumab (Treatment) 
hMS-1 vs Tractuzumab: 
• Less viral titer Less lung injury  
• Fewer histopathological changes  
• Less decrease in the body weight 
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• More survival rate 
[54] Comparator 
trial 
Ad5-
hCD26-
transduced 
mice 
No Either 1d before or 1 d after 
inoculation 
IV mAb 4C2h (Prophylaxis and 
treatment) or no treatment 
Decreased Viral titer  
[51] Comparator 
trial 
Rhesus 
macaques 
No Treatment group (#3): INF-α-2a SQ 
+ Ribavirin IV  
No treatment group (#3) 
Decreased in oxygen saturation, 
increased white blood cells and 
neutrophils on day one more in no 
treatment  
Chest radiograph in the treated group 
showed light infiltration in a single lobe 
by day 2, and 3. 
Decrease viral load in treatment group.  
Untreated groups: increased in 
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perivascular infiltrates.  
[55] Comparator 
trial 
Ad5-
hCD26-
transduced 
mice 
No Treatment group: Intranasal peptide 
HR2P-M2 200mcg 6h before 
inoculation (Prophylaxis) 
Control group (no treatment) 
Decreased viral titer  
1st gp: 200 mcg intranasal HR2P-M2 
2nd gp: 2000 U intranasal INF-β 
3rd gp: Combination 
4th gp: no treatment 
6h before inoculation 
(prophylaxis) 
Decreased viral titer in all treated group 
compared with the control group with 
complete clearance in mice which 
received combination treatment. 
1st gp: 200 mcg intranasal HR2P-M2 
2nd gp: 2000 U intranasal INF-β 
3rd gp: Combination 
Viral inhibition in all treated group with 
the greatest reduction in the combination 
group. greater reduction in viral titer in 
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4th gp: no treatment 
12 and 36 h after inoculation 
(treatment) 
the HR2P-M2 alone vs INF-β alone.  
Reduced histopathologic change in INF- 
β and HR2P-M2 treated group with the 
greatest reduction in the combination 
group 
[56] 
 
Comparator 
trial 
hDPP-4 
Tg mice 
No 1st gp: NbMS10-Fc single dose 
2nd gp: Trastuzumab 
Before inoculation (prophylaxis) 
Better survival rate  
Steady weight compared with sharply 
decreased in the weight on the control 
group  
1st gp: NbMS10-Fc single dose 
2nd gp: Trastuzumab 
3d after inoculation (treatment) 
Better survival rate  
Less weight loss 
 
[52] Comparator 
trial 
12 healthy 
common 
No 1st gp: no treatment 
2nd gp: Mycophenolate mofetil 
Lopinavir/Ritonavir and INF- β-1b have 
a better clinical score, less weight 
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Marmosets intraperitoneal after 8hr of 
inoculation 
3rd gp: + Ritonavir PO at 6, 30, and 
54 hrs after inoculation, 
4th gp: INF- β-1b SQ at 8 and 56 hrs 
post inoculation. 
(Treatment) 
reduction,  less radiological and 
pathological finding, and lower viral load 
in the lung  and in the extrapulmonary   
The Mycophenolate has a higher viral 
load vs control group.  
The fatality rate was higher in untreated, 
and Mycophenolate vs treated groups  
[57] Comparator 
trial 
Ad5-
hDPP4-
transduced 
mice 
No 1st gp: Intraperitoneal 100 or 500 mcg 
(5 or 25 mg/kg) of SAB-301 
2nd gp: negative control Tc hIgG 500 
mcg 
3rd gp: no treatment 
12 hr before inoculation 
(prophylaxis) 
viral load was lower in SAB-301 vs Tc 
hIgG group at day 1  
The viral titer was lowest in the 500mcg 
vs Tc hIgG and control   
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 * mAb: monoclonal antibodies; INF: interferon; gp: group;  
1st gp:  intraperitoneally single dose 
500 mcg SAB-301 antibody,  
2nd gp: intraperitoneally single dose 
Tc hIgG 
3rd gp: no treatment  
1-2 hrs of inoculation (Treatment) 
On day 1 and 2 post infection: 
• Viral titer in SAB-301 antibody group 
was below the detection level vs 
control or Tc hIgG  
•  
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Table 3: A summary of human studies of the use of anti-viral therapy for the treatment of MERS-CoV infection 
 Study type Total # Supportive 
therapy 
Treatment plan Outcome 
 
[60] Retrospective 
cohort study 
Treatment 
group (n=20) 
versus control 
group (n=24) 
44 
patients 
Yes  SQ PEG-INF α-2a + 
PO Ribavirin for 8-10 days: 
 
Survival rate after 14 days 
was 70% versus 29% (P= 
0.004) but no change after 
28 days (30% versus 17%; 
P= 0.054) 
Decreased hemoglobin 
level as a side effect of 
ribavirin  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
47 
 
[58] Retrospective 
observational 
studies 
Two 
patients 
Yes 1st patient: SQ PEG-INF α- 2b + PO Ribavirin  There was a drop in 
hemoglobin level 
The patient improved and 
discharge home 
Yes  2nd patient: SQ PEG-INF α- 2b 1 for 3 days + 
Ribavirin PO  
After 14 days the patient 
recovered from MERS-
CoV. 
Died after two months as a 
result of MDR and hospital-
acquired infections 
[59] Retrospective 
observational 
studies 
5 patients Yes Ribavirin for 5 days + SQ INF α-2b  Died from multi-organ 
failure 
Yes Ribavirin for 5 days + SQ INF α-2b for 2 
doses. 
Drop in in platelet 
Died from multi-organ 
failure 
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Yes Ribavirin PO for 5 days + SQ INF α-2b. Patient developed 
pancreatitis 
Died from multi-organ 
failure 
Yes Ribavirin PO for 5 days + SQ INF α-2b for 2 
doses. 
hemoglobin dropped and 
bilirubin  increased and 
dialysis was  required 
Died from multi-organ 
failure 
Yes Ribavirin PO for 5 days + SQ INF α-2b for 2 
doses. 
Increased lipase 
Died from multi-organ 
failure 
[63] Case report 1 patient No Lopinavir/Ritonavir PO + Ribavirin PO + 
PEG-INF α-2a SQ 
Improved 
No fever after 2 days 
Discharge after 9 days 
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Developed hemolytic 
anemia, electrolyte 
disturbance, and kidney and 
liver dysfunction. 
[62] Retrospective 
Cohort Study 
24 
patients 
Yes 1st gp: 13 pts INF- α-2a SQ + PO Ribavirin  
2nd gp: 11 pt INF-β-1a + PO Ribavirin 
The fatality rate was 85% in 
INF-α-2a vs 64% in INF-β-
1a.  
[65] Case series 2 patients Yes  1st patient as treatment and 2nd patient as 
prophylaxis 
SQ PEG-INF- α-2b: 
Ribavirin PO  
Complete recovery and 
discharge home. 
[71] case series 11 ribavirin and interferon-alfa 2a Survival of all patients 
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[70] Randomized 
control trial 
The enrollment began 
in Nov. 2016 
100mg Lopinavir/100mg Ritonavir PO q12h 
for 14 days + INF- β1b 0.25mg/ml SQ on 
alternative days for 14 days. 
Result is not yet published 
[66] Case series 23 Interferon beta 18/23 (78.3) 
[66] Case series 8 Interferon alpha 6/8 (75) 
[66] Case series 19 Ribavirin 13/19 (68.4) 
[66] Case series 8 Mycophenolate mofetil 8/8 (100) 
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* PEG-INF: pegylated interferon; gp: group 
[72] case report 1 ribavirin and interferon-alfa 2a  
day 12 from onset 
died 
[67] case series 6 ribavirin and interferon-alfa 2b 3/6 (50) 
